Showing results (151-160 of 181) with videos related to

Sort By:
Pageof 19
Emerging Infectious Diseases|July 23, 2024
Standardized Phylogenetic Classification of Human Respiratory Syncytial Virus below the Subgroup LevelStephanie Goya, Christopher Ruis, Richard A Neher, et al.
Open Forum Infectious Diseases|April 8, 2020
Determinants of Fatal Outcome in Patients Admitted to Intensive Care Units With Influenza, European Union 2009-2017Cornelia Adlhoch, Joana Gomes Dias, Isabelle Bonmarin, et al.
Influenza and Other Respiratory Viruses|November 11, 2017
2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among childrenEsther Kissling, Marta Valenciano, Francisco Pozo, et al.
Influenza and Other Respiratory Viruses|May 21, 2025
COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care NetworkCharlotte Laniece Delaunay, Nuno Verdasca, Susana Monge, et al.
Ecohealth|May 20, 2017
Epidemiological Risk Factors for Animal Influenza A Viruses Overcoming Species BarriersKate A Harris, Gudrun S Freidl, Olga S Munoz, et al.
Vaccine|May 4, 2024
Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in EuropeMarine Maurel, Clara Mazagatos, Luise Goerlitz, et al.
Influenza and Other Respiratory Viruses|April 17, 2018
Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I-MOVE multicentre test-negative case-control study, 2011/2012-2016/2017Marta Valenciano, Esther Kissling, Amparo Larrauri, et al.
Vaccine: X|October 30, 2019
Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016-17 and 2017-18)Esther Kissling, Francisco Pozo, Silke Buda, et al.
Influenza and Other Respiratory Viruses|November 11, 2024
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024Lore Merdrignac, Charlotte Laniece Delaunay, Nuno Verdasca, et al.
Vaccine|March 15, 2022
Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?Lotus L van den Hoogen, Gaby Smits, Cheyenne C E van Hagen, et al.
Pageof 19